The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.

Yuan, Huiyang; Qin, Xin; Wang, Jing; Yang, Qingya; Fan, Yidong; Xu, Dawei

Yuan, Huiyang; Qin, Xin; Wang, Jing; Yang, Qingya; Fan, Yidong; Xu, Dawei.

Affiliation

Yuan H; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Qin X; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Wang J; Department of Urologic Oncology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Yang Q; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Fan Y; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Xu D; Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden.

Front Immunol ; 13: 971142, 2022.

Article de En | MEDLINE | ID: mdl-36131921

Sujet(s)
Mots clés

ccRCC; cuproptosis; immune checkpoint inhibitors; immunotherapy; prognosis; targeted therapy

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Néphrocarcinome / Tumeurs du rein Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Front Immunol Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google